Buy Takhzyro (lanadelumab)

Buy Takhzyro (lanadelumab). Takhzyro (lanadelumab) is a medicine for preventing HAE attacks in people 12 and older. It comes in a solution for injection in single-dose vials.

Takhzyro (lanadelumab) is a revolutionary treatment for hereditary angioedema, a rare genetic disorder that causes severe swelling in various parts of the body. This groundbreaking medication has changed the lives of many patients by providing long-term prevention of attacks and reducing the frequency of symptoms. In this article, we will explore the benefits of Takhzyro, how it works, and why it has become the go-to treatment for hereditary angioedema.

Takhzyro, also known by its generic name lanadelumab, is a monoclonal antibody that targets and blocks plasma kallikrein, a key enzyme in the production of bradykinin. Bradykinin is responsible for the increased permeability of blood vessels, which leads to the characteristic swelling seen in hereditary angioedema. By inhibiting plasma kallikrein, Takhzyro helps to prevent the excessive production of bradykinin, thereby reducing the frequency and severity of attacks in patients with hereditary angioedema.

How does Takhzyro (lanadelumab) work?

Hereditary angioedema (HAE) causes severe swelling in the skin and mucous membranes. This swelling can happen in the face, throat, arms, and legs.

People with HAE have too much bradykinin, a hormone that makes blood vessels swell. This leads to fluid leaking into tissues, causing swelling. Takhzyro’s active ingredient, lanadelumab, blocks kallikrein in the blood. This reduces the symptoms of HAE.

Where has Takhzyro (lanadelumab) been approved?

Takhzyro (lanadelumab) is approved for HAE prevention by:

• Food and Drug Administration (FDA), USA, August 23, 2018
• European Medical Agency (EMA), European Union, November 22, 2018.

This medicine might be approved in other places too. If you have questions about its approval in a specific country, contact our support team.

How is Takhzyro (lanadelumab) taken?

The usual dose is:

• 300 mg given as a subcutaneous injection every 2 weeks.

Depending on symptoms and side effects, the dose might need to be adjusted.

For more details on Takhzyro (lanadelumab) dosage and use, see the official prescribing information in our resources section.

Note: Always talk to your doctor about the right dose for you and any drug interactions.

How does Takhzyro work?

Takhzyro is administered through subcutaneous injections, typically once every two weeks. The medication works by binding to plasma kallikrein and preventing it from activating bradykinin. This, in turn, reduces the swelling and inflammation associated with hereditary angioedema. Patients who have been prescribed Takhzyro often report a significant decrease in the number of attacks they experience, as well as a decrease in the severity of symptoms when attacks do occur. Buy Takhzyro (lanadelumab)

Are there any known side effects or adverse reactions of Takhzyro (lanadelumab)?

Common side effects include:

• injection site reactions, such as:
  • pain
  • skin redness
  • bruising
  • discomfort
  • swelling.

Takhzyro (lanadelumab) can be dangerous for a fetus. It’s best to avoid pregnancy and breastfeeding while using this medicine.

What are the benefits of Takhzyro?

• Long-term prevention: Takhzyro is designed to provide long-term prevention of hereditary angioedema attacks, allowing patients to lead more normal and productive lives.
• Reduced frequency of attacks: Many patients on Takhzyro report a significant reduction in the frequency of attacks, with some experiencing months between episodes.
• Improved quality of life: By reducing the physical and emotional burden of hereditary angioedema, Takhzyro has been shown to improve the overall quality of life for patients. Buy Takhzyro (lanadelumab)

Is Takhzyro safe and effective?

Clinical trials have demonstrated the safety and effectiveness of Takhzyro in preventing hereditary angioedema attacks. The most common side effects reported by patients include injection site reactions, headache, and upper respiratory tract infection. However, these side effects are typically mild and well-tolerated. Takhzyro has been approved by the FDA for use in patients aged 12 and older and has quickly become the treatment of choice for many individuals with hereditary angioedema.

Stelara (ustekinumab)